Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar Pollinosis

Trial Profile

Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar Pollinosis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Japanese cedar pollen allergy immunotherapy Torii Pharmaceutical (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 10 Nov 2014 New trial record
    • 14 Sep 2012 According to a Torii Pharmaceutical media release, the company will conduct the full analysis of the study results and plans to submit a New Drug Application in Japan in March 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top